Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research into Tasmanian devils provides new insights into how and why we reproduce as a species.
By talking about her cancer, she hopes to help destigmatize it.
The approvals amount to a “game-changer for how we think about treating different groups of patients with AML.”
A Phase II trial tested SurVaxM in combination with standard therapy for the aggressive brain cancer.
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
Why the head of the world’s largest cancer organization braved dirt roads and crowded urban streets to reach impoverished cancer centers
“SNL” alum and cancer survivor Vanessa Bayer has written a book with lessons for kids—and adults.
Just 13% of men who opted for active surveillance over treatment adhered to the recommended monitoring schedule.
Results of a study indicate that these trials can be good therapeutic options for people with heavily pretreated ovarian cancer.
More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.
RT America has been exaggerating the health hazards of new high-speed cell phone signals, spreading fear about U.S. tech.
We know that skin cancer is the most common type of cancer in the U.S. and it can be costly, disfiguring, and even deadly.
The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.
Antibody-drug conjugate carries a chemotherapy drug directly to cancerous B cells.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.